Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $122.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price target upped by Wedbush from $105.00 to $122.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other equities research analysts have also issued reports on DNTH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Stock Down 0.9%

Shares of NASDAQ DNTH opened at $108.92 on Wednesday. Dianthus Therapeutics has a twelve month low of $18.08 and a twelve month high of $114.55. The firm has a fifty day simple moving average of $94.72 and a 200 day simple moving average of $80.65. The company has a market capitalization of $5.95 billion, a PE ratio of -26.25 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, equities analysts expect that Dianthus Therapeutics will post -3.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ryan Savitz sold 31,249 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 253,779 shares of company stock worth $25,931,495 in the last ninety days. 3.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the period. American Century Companies Inc. raised its holdings in Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after purchasing an additional 6,323 shares during the period. Invesco Ltd. lifted its stake in shares of Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after buying an additional 4,962 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after buying an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the 2nd quarter worth $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.